SINTX Technologies received a new U.S. patent for its antipathogenic fabric technology, enhancing licensing and market opportunities.
Quiver AI Summary
SINTX Technologies, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering their antipathogenic fabric technology, enhancing the company’s intellectual property (IP) rights. This new patent complements an earlier one focused on the composition of their antipathogenic fibrous materials, providing comprehensive protection for both the material and its production methods. The patents position SINTX for increased licensing and partnership opportunities across markets such as medical textiles and filtration. SINTX's technology demonstrates significant effectiveness against pathogens, including a 99.97% reduction of SARS-CoV-2 in laboratory conditions, addressing a substantial market opportunity estimated at $30 billion in infection prevention products. The company aims to pursue collaborations in various sectors given its strengthened IP protection.
Potential Positives
- Issuance of a new U.S. Patent bolsters SINTX's competitive advantage and expands its intellectual property portfolio, which covers both material composition and manufacturing methods.
- This dual coverage enhances the company's potential for licensing and partnership opportunities across key markets, including medical textiles and filtration media.
- The press release highlights a significant market opportunity for infection prevention solutions, with a reported addressable market of approximately $30 billion.
- The inclusion of peer-reviewed scientific validation regarding the efficacy of silicon nitride in inactivating pathogens strengthens the credibility of the company’s technology and potential applications.
Potential Negatives
- Despite the positive announcement regarding patent allowances, the press release contains numerous forward-looking statements that include various risks and uncertainties, which may lead to skepticism about the company's ability to achieve its commercial objectives.
- The reliance on forward-looking statements indicates that there may be challenges in executing the company's business strategy, such as protecting and enforcing its intellectual property and gaining necessary regulatory approvals.
- The potential for market acceptance of new technologies is uncertain, which could hinder the company's growth in the competitive infection-prevention market.
FAQ
What is the significance of SINTX's new U.S. patent?
The new U.S. patent enhances SINTX's competitive advantage and protects its antipathogenic fabric technology across multiple markets.
How does the patent strengthen SINTX's licensing opportunities?
This patent allows SINTX to defend and license both the materials and manufacturing methods, enhancing commercialization potential with partners.
What are the applications of SINTX's antipathogenic fabric technology?
The technology has applications in medical textiles, filtration media, wound care, and personal protective equipment (PPE).
What is the market potential for SINTX's technologies?
The accessible market for SINTX's platform is approximately $30 billion across various sectors, including healthcare and infection prevention.
How effective is silicon nitride in inactivating pathogens?
Laboratory results show that silicon nitride can achieve up to a 99.97% reduction of infectious SARS-CoV-2 within minutes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SINT Insider Trading Activity
$SINT insiders have traded $SINT stock on the open market 27 times in the past 6 months. Of those trades, 27 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SINT stock by insiders over the last 6 months:
- GREGG R. HONIGBLUM (Chief Investment Officer) has made 15 purchases buying 64,000 shares for an estimated $209,826 and 0 sales.
- ERIC K. OLSON (President and CEO) has made 9 purchases buying 24,975 shares for an estimated $65,557 and 0 sales.
- MARK LEWIS ANDERSON has made 2 purchases buying 15,000 shares for an estimated $44,800 and 0 sales.
- JAY M MOYES purchased 3,000 shares for an estimated $10,756
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SINT Analyst Ratings
Wall Street analysts have issued reports on $SINT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 09/22/2025
To track analyst ratings and price targets for $SINT, check out Quiver Quantitative's $SINT forecast page.
Full Release
New U.S. Patent reinforces competitive advantage and enables broader licensing and product opportunities across key markets
SALT LAKE CITY, Utah, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application containing method claims covering the Company’s antipathogenic fabric technology.
This development builds upon SINTX’s previously announced patent allowance for its Antipathogenic Fibrous Materials composition patent, expanding the Company’s Intellectual Property (IP) to protect both the material itself and the processes that bring it to market. This dual coverage strengthens the Company’s competitive advantage, enhances licensing and partnership opportunities, and broadens potential applications across medical textiles, filtration media, and other infection-prone surfaces.
These two patent families create a comprehensive IP competitive barrier around SINTX’s surface-level pathogen-inactivation technology, covering applications in wound dressings, surgical drapes and gowns, filtration media, personal protective equipment (PPE), and high-touch clinical surfaces.
“We are excited to announce the allowance of our Method Patent for Antipathogenic Fibrous Materials, marking a significant milestone that strengthens and broadens the protection of our proprietary silicon nitride technology platform.” said Eric K. Olson, Chairman and CEO of SINTX Technologies. “This newly allowed patent complements the recently issued U.S. Patent No. 12,433,356, granted on October 7, 2025, which covers the composition of silicon nitride for antipathogenic fibrous materials. Together, these patents reinforce SINTX’s leadership in infection-resistant material innovation and expand the Company’s IP protection to cover both the composition of its fabrics and methods by which they are produced and applied. We believe this dual-layer IP foundation significantly enhances the licensing and commercialization potential of our platform.”
Lisa Marie, Del Re, Chief Commercial Officer, added, “With method claims, we can now defend and license the manufacturing and application pathways that unlock silicon nitride’s antipathogenic performance in textiles and surfaces. This is crucial as we engage with potential wound-care, filtration, and medical-textile partners.”
Scientific foundation and external validation
“Peer-reviewed work has repeatedly shown rapid inactivation of coronaviruses and broad antimicrobial activity associated with silicon nitride, including recent data reporting up to ~99.97% reduction of infectious SARS-CoV-2 within minutes under lab conditions,” said Dr. Ryan Bock, Chief Technology Officer. “Non-woven fabrics containing optimized Si₃N₄ powder have also provided significant viral reduction, demonstrating again that our silicon nitride platform is suitable for unlocking antipathogenic properties in a wide range of products.”
Note: Laboratory antiviral/antimicrobial results support the materials platform and are distinct from any cleared device indications.
Market context
Infection-prevention remains a large, multi-segment opportunity. SINTX previously characterized the accessible market for its platform as ~$30B across medical textiles, wound management, filtration/PPE, and healthcare infrastructure—an opportunity now underpinned by composition + method coverage.
At the care-delivery level, ~1 in 31 U.S. hospital patients has at least one healthcare-associated infection (HAI) on any given day, with substantial economic burden—reinforcing demand for passive, surface-level solutions that work continuously at the point of contact. (CDC data; cost ranges widely across HAI types.)
SINTX plans to pursue licensing and co-development partnerships with textile, wound care , and filtration/PPE partners. The dual-patent estate allows SINTX to license both materials embodiments and process methods, enabling flexible deal structures including upfronts, milestones, and royalties across multiple points in the supply-chain node.
For more information, visit www.sintx.com .
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Through innovation and strategic partnerships, SINTX continues to expand its portfolio across multiple markets.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Forward-looking statements often include words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “should,” “will,” and similar expressions. Examples in this release include, without limitation, statements regarding the anticipated commercial, licensing, and partnership potential of SINTX’s intellectual property (including newly allowed claims), the Company’s plans to pursue licensing, co-development, or other commercialization arrangements, expectations about market opportunities and expansion into new markets, and the Company’s competitive positioning. These statements are subject to risks and uncertainties, including SINTX’s ability to execute its business strategy; protect and enforce its intellectual property; successfully enter into and perform under licensing and partner relationships; obtain necessary regulatory approvals; achieve market acceptance of new technologies; general economic and industry conditions; and other risks described in SINTX’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections of its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as required by law, SINTX undertakes no obligation to update or revise any forward-looking statements.
Contact:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
[email protected]
SINTX Technologies, Inc.
801.839.3502
[email protected]
